AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 2, 2003, Pages 665-669

  Visalli, Melissa A ^a   Murphy, Ellen ^a   Projan, Steven J ^a   Bradford, Patricia A ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIFLAVINE; AMPICILLIN; CARRIER PROTEIN; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; ERYTHROMYCIN; ETHIDIUM BROMIDE; GENE PRODUCT; IMIPENEM; MINOCYCLINE; NOVOBIOCIN; PROTEIN ACRAB; PROTEIN ACRRAB; TIGECYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM MUTANT; CONTROLLED STUDY; ESCHERICHIA COLI; GENE INSERTION; GENE MAPPING; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEUS MIRABILIS; TRANSPOSON;

CARRIER PROTEINS; DNA TRANSPOSABLE ELEMENTS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI PROTEINS; MEMBRANE PROTEINS; MINOCYCLINE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROTEUS MIRABILIS;

EID: 0037309748     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.2.665-669.2003     Document Type: Article

References (25)

1. Altschul, S. F., T. L. Madden, A. A. Schaffer, J. Zhang, Z. Zhang, W. Miller, and D. J. Lipman. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:3389-3402.
2. Boucher, H. W., C. B. Wennersten, and G. M. Eliopoulos. 2000. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob. Agents Chemother. 44:2225-2229.
3. Fralick, J. A. 1996. Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli. J. Bacteriol. 178:5803-5805.
4. Gales, A. C., and R. N. Jones. 2000. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical isolates. Diagn. Microbiol. Infect. Dis. 36:19-36.
5. Hoellman, D. B., G. A. Pankuch, M. R. Jacobs, and P. A. Appelbaum. 2000. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob. Agents Chemother. 44:1085-1088.
6. Jacoby, G. A. 1994. Extrachromosomal resistance in gram-negative organisms: the evolution of β-lactamase. Trends Microbiol. 2:358-361.
7. Kopytek, S. J., J. C. D. Dyer, G. S. Knapp, and J. C. Hu. 2000. Resistance to methotrexate due to AcrAB-dependent export from Escherichia coli, Antimicrob. Agents Chemother. 44:3210-3212.
8. Lederberg, J., and E. M. Lederberg. 1952. Replica plating and indirect selection of bacterial mutants. J. Bacteriol. 63:399-406.
9. Lesley, S. A., J. Graziano, C. Y. Cho, M. W. Knuth, and H. E. Klock. 2002. Gene expression response to misfolded protein as a screen for soluble recombinant protein. Protein Eng. 15:153-160.
10. Levy, S. 1994. Balancing the drug-resistance equation. Trends Microbiol. 2:341-342.
11. Linde, H. J., F. Notka, C. Irtenkauf, J. Decker, J. Wild, H. H. Niller, P. Heisig, and N. Lehn. 2002. Increase in MICs of ciprofloxacin in vivo in two closely related clinical isolates of Enterobacter cloacae. J. Antimicrob. Chemother. 49:625-630.
12. Ma, D., D. N. Cook, J. E. Hearst, and H. Nikaido. 1994. Efflux pumps and drug resistance in gram-negative bacteria. Trends Microbiol. 2:489-493.
13. Mazzariol, A., T. Yutaka, T. M. Kanegawa, G. Cornaglia, and H. Nikaido. 2000. High-level flouroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA. Antimicrob. Agents Chemother. 44:3441-3443.
14. McMurry, L. M., M. Oethinger, and S. Levy. 1998. Overexpression of marA, soxS, or acrAB produces resistance to triclosan in laboratory and clinical strains of Escherichia coli. FEMS Microbiol. Lett. 166:305-309.
15. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A5, 5th ed., vol. 17. National Committee for Clinical Laboratory Standards, Wayne, Pa.
16. Nikaido, H. 1996. Multidrug efflux pumps of gram-negative bacteria. J. Bacteriol. 178:5853-5859.
17. Okusu, H., D. Ma, and H. Nikaido. 1996. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J. Bacteriol. 178:306-308.
18. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.
19. Piddock, L. V., D. G. White, K. Gensberg, L. Pumpbe, and D. J. Griggs. 2000. Evidence for an efflux pump mediating multiple antibiotic resistance in Salmonella enterica serovar Typhimurium. Antimicrob. Agents Chemother. 44:3118-3121.
20. Roberts, M. C. 1994. Epidemiology of tetracycline-resistance determinants. Trends Microbiol. 2:353-357.
21. Sambrook, J. E., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
22. Sanchez, L., W. Pan, M. Vinas, and H. Nikaido. 1997. The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump. J. Bacteriol. 179:6855-6857.
23. Srikumar, R., T. Kon, N. Gotoh, and K. Poole. 1998. Expression of Pseudomonas aeruginosa multidrug efflux pumps MexA-MexB-OprM and MexC-MexD-OprJ in a multidrug-sensitive Escherichia coli strain. Antimicrob. Agents Chemother. 42:65-71.
24. Sum, P. E., and P. J. Petersen. 1999. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett. 9:1459-1462.
25. Van Bambeke, F., E. Balzi, and P. M. Tulkens. 2000. Antibiotic efflux pumps, Biochem. Pharmacol. 60:457-470.